Intensifying Competition in the Medical Device Industry Involving Global M&A
First written in FY2018. 8 of 9 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2026: 21 of 39 companies on the "Worse" side.
39 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. In addition, there were no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition in the medical device industry amid global M&A activity. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition in the medical device industry amid global M&A activity. - FY2021-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition in the medical device industry amid M&A and sales partnerships. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition in the medical device industry amid M&A and sales partnerships. - FY2020-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition in the medical device industry amid M&A and sales partnerships. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the three-month period ended [the first quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition in the medical device industry amid global M&A and sales partnerships. - FY2019RestatedAnnual report
「Companies in the industry are also pursuing initiatives to strengthen their competitiveness, such as entering other treatment areas and expanding their sales scale through M&A and sales partnerships with other companies.」
Competition to expand treatment areas and sales scale through M&A and sales partnerships continues to be cited as part of the industry environment. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company has disclosed that there has been no material change regarding the risk of intensifying competition in the medical device industry amid global M&A activity. - FY2018First statedAnnual report
「In addition, M&A is being actively pursued on a global scale to expand business areas and acquire innovative, high-quality products, further intensifying competition.」
The Company identifies the increasing activity of global M&A in the medical device industry and intensifying competition to acquire business areas and products as a new external risk.